News |

 Upcoming Events

 

1

 

Cambridge Pancreatic Cancer Symposium 2019

The next symposium will be held on 9th – 10th May at the Cancer Research UK Cambridge Institute, University of Cambridge. The programme for the symposium can be found here.

Registration has now closed. Please contact Aarthi.Gopinathan@cruk.cam.ac.uk if you have any questions.



Please note:
  1. Due to the current cashless system at the Cambridge Institute, symposium attendees will be unable to use the cafeteria on-site to purchase refreshments. We apologise for any inconvenience this may cause.
  2. There is no assigned visitor parking for the institute. Symposium attendees will have to park at one of the on-site public car parks. Please see the site map for details.


Speakers



Lynn M. Matrisian, PhD, MBA

frameLynn is Chief Science Officer at the Pancreatic Cancer Action Network, based in Manhattan Beach, CA and Washington DC, USA. She focuses on understanding and impacting the scientific and medical activities within the pancreatic cancer field to advance the organizations goal to double survival from pancreatic cancer by the year 2020.

More about Lynn →


Pr L. Zitvogel

framePr L. Zitvogel, clinical oncologist and research director, has been actively contributing to the field of cancer immunology and immunotherapy since 1992. She brought together basic and translational research, including the design of cancer therapies through combined animal studies and Phase I patient trials.

More about Pr L. Zitvogel →


Dr. Cristian Tomasetti

frameCristian is an Associate Professor at Johns Hopkins University with appointments in the Division of Biostatistics and Bioinformatics, Department of Oncology (Sidney Kimmel Comprehensive Cancer Center) and the Department of Biostatistics (Bloomberg School of Public Health).

More about Cristian →


Christine Iacobuzio-Donahue MD PhD

frameChristine is a board certified Anatomic Pathologist with specialty training in gastrointestinal pathology and cancer genetics. She currently serves as an Attending Physician in Pathology, Director of the David M. Rubenstein Center for Pancreatic Cancer Research, and Director of the Medical Donation (Rapid Autopsy) Program at Memorial Sloan Kettering Cancer Center in New York City, NY.

More about Christine →


Ken Olive

frameKen began his doctoral studies in 1998 in the laboratory of Tyler Jacks at the MIT Center for Cancer Research, investigating the neomorphic effects of mutant p53 in a mouse model of Li-Fraumeni Syndrome. While at MIT, he also helped develop a conditional mutant model of advanced lung adenocarcinoma.

More about Ken →


Stephan Herzig

frameStephan is Director of the Institute for Diabetes and Cancer (IDC) at Helmholtz Center Munich (HMGU), full professor for molecular metabolic control at the medical faculty of the Technical University Munich and honorary professor at the University of Heidelberg.

More about Stephan →


Dr John Maher

frameDr John Maher leads the "CAR Mechanics" group within King's College London, which is focused on the development of adoptive immunotherapy using CAR and gamma delta T-cells. He played a key role in the early development of second generation CAR technology and is chief investigator of a Phase 1 CAR T-cell clinical trial in head and neck cancer.

More about John →


Dr. Christian Frezza

frameDr. Christian Frezza is Programme leader at the MRC Cancer Unit, Cambridge Cancer Center, at the University of Cambridge, UK. He studied Medicinal Chemistry at the University of Padova, Italy, and gained his MSc in 2002, after a period of research on mitochondrial toxicity induced by photoactivable anticancer drugs.

More about Christian →


Stephen Pereira

frameDr. Christian Stephen Pereira, Professor of Hepatology & Gastroenterology at UCL and Honorary Consultant Gastroenterologist in PancreaticoBiliary Medicine at University College Hospital and The Royal Free Hospital. The research interests of the Centre for HPB Cancer within the UCL Division of Medicine concentrate on the pathogenesis, diagnosis and treatment of biliary tract and pancreatic cancer, as well as the benign conditions primary sclerosing cholangitis and autoimmune pancreatitis

More about Steve →


Acknowledgements

The Cambridge Pancreatic Cancer Centre gratefully acknowledges support from the following organisations for providing funding for the symposium: